- Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and PFS in Refractory NSCLC Patients
- AffyImmune Announces Plenary Oral Presentation on ICAM-1 Directed CAR T Therapy AIC100
- ALX Oncology Announces Encouraging Final Results from Ph 1 Trial of Evorpacept + SOC Treatment in Patients with B-cell NHL
- Ankyra Therapeutics Announces Ph 1 Data and the first patient has been dosed with tolododekin alfa and cemiplimab
- Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000)
- Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa
- Boehringer’s new zongertinib data demonstrates durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
- Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042
- BriaCell Presents Survival and Clinical Benefit from Ph 2 of Bria-IMT in metastatic breast cancer
- Coherus Presents Promising Early Clinical Data from Ph 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic SCCHN
- Data from First-in-Human Trial targeting CISH, a Novel Immune Checkpoint, in Patients with Metastatic Colorectal Cancer
- EpimAb Biotherapeutics Announced Clinical results for EMB-01 in CRC
- HUTCHMED announced new and updated data from several studies of savolitinib, fruquintinib and surufatinib
- ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML
- ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery
- IN8bio to Present Clinical Data from Gamma-Delta T Cell Platform
- KEYTRUDA as Perioperative Treatment With SOC Adjuvant Therapy Significantly Improved EFS Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
- Marengo to Share Updated Clinical Results from STARt-001 Ph 1/2 Trial of Invikafusp Alfa Monotherapy Activity in PD1-Resistant Tumors
- Medicenna Presents Results from the ABILITY-1 Clinical Trial
- Nuvectis Pharma Provides Poster Presentation Highlights for NXP900
- PDS Biotech Announces PDS01ADC Clinical Data
- Plexium Announces Multiple Presentations with Selective Monovalent Degrader Programs Targeting SMARCA2, IKZF2 and CDK2
- Purple Biotech Reports Final Data from Ph 2 Study of CM24 in Pancreatic Cancer Patients
- OBI Pharma Announces Poster Presentations for OBI-992 and OBI-902 ADCs, GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
- Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant NSCLC
- Senti Bio’s SENTI-202 Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
- SparX to Present Ph 1 Clinical Updates of SPX-303
- Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma
- Sutro Biopharma Highlighted Next-Generation Exatecan and Dual-Payload ADC Programs
- TuHURA Biosciences and Kineta Present Updated Results from Ph 1/2 Study of KVA12123 and Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma
- Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy
- Zymeworks Presents New Data from Multiple Development Programs
